


BI-2865

Chemical Properties

CAS No. : 2937327-93-8
 Formula: C₂₃H₂₇N₇O₂S
 Molecular Weight: 465.57
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
 Actual storage temperature shall be subject to the COA.



Biological Description

Description	BI-2865 is a non-covalent pan-KRAS inhibitor. BI-2865 binds to KRAS WT, G12C, G12D, G12V, and G13D mutants with KD values of 6.9, 4.5, 32, 26, and 4.3 nM, respectively. BI-2865 showed antiproliferative activity in BaF3 cells expressing KRAS G12C, G12D, or G12V mutants[1]. BI-2865 showed antiproliferative activity on BaF3 cells expressing KRAS G12C, G12D or G12V mutants, with an average IC ₅₀ value of approximately 140 nM.[1]
Targets(IC ₅₀)	Ras, Kras
In vitro	METHODS: BaF3 cells expressing isogenic KRAS mutants of the indicated KRAS or expressing G12C, G12D or G12V mutant KRAS were treated in the absence of IL3 for 5 days to determine the effect on proliferation. RESULTS BI-2865 inhibited the proliferation of isogenic G12C, G12D or G12V mutant KRAS expressing BaF3 with an IC ₅₀ value of 140 nM. [1]

Solubility Information

Solubility	DMSO: 240 mg/mL (515.5 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1479 mL	10.7395 mL	21.479 mL
5 mM	0.4296 mL	2.1479 mL	4.2958 mL
10 mM	0.2148 mL	1.074 mL	2.1479 mL
50 mM	0.043 mL	0.2148 mL	0.4296 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kim D, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. *Nature*. 2023 Jul;619(7968): 160-166.

Guo Y, Tian J, Guo Y, et al. Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β -catenin. *Cell Reports*. 2023, 42(12).

Guo Y, Hu C, Cai K, et al. KRAS inhibitors may prevent colorectal cancer metachronous metastasis by suppressing TGF- β mediated epithelial-mesenchymal transition. *Molecular Medicine Reports*. 2025, 31(1): 1-12.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481